科伦博泰生物-B：SKB2641L肺癌III期成功 SKB105达成授权

中金公司2025-12-11

近日，公司宣布：1）TROP2 ADC芦康沙妥珠单抗（SKB264）联合帕博利珠单抗（Keytruda）1L治疗PD-L1 阳性非小细胞肺癌（NSCLC）的国内III期临床OptiTROP-Lung05 达到主要终点。2）公司与Crescent Biopharma达成合作，将ITGB6 ADCSKB105 海外权益以8,000 万美元首付款和高达12.5 亿美元的里程碑授予Crescent，并以2...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2590512615?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-11 00:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2590512615","market":"hk","top_or_hot":-1,"title":"科伦博泰生物-B：SKB2641L肺癌III期成功 SKB105达成授权","media":"中金公司","content":"<div>\n<p>近日，公司宣布：1）TROP2 ADC芦康沙妥珠单抗（SKB264）联合帕博利珠单抗（Keytruda）1L治疗PD-L1 阳性非小细胞肺癌（NSCLC）的国内III期临床OptiTROP-Lung05 达到主要终点。2）公司与Crescent Biopharma达成合作，将ITGB6 ADCSKB105 海外权益以8,000 万美元首付款和高达12.5 亿美元的里程碑授予Crescent，并以2...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211184208a6995d1f&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>科伦博泰生物-B：SKB2641L肺癌III期成功 SKB105达成授权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n科伦博泰生物-B：SKB2641L肺癌III期成功 SKB105达成授权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-11 00:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211184208a6995d1f&s=b><strong>中金公司</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近日，公司宣布：1）TROP2 ADC芦康沙妥珠单抗（SKB264）联合帕博利珠单抗（Keytruda）1L治疗PD-L1 阳性非小细胞肺癌（NSCLC）的国内III期临床OptiTROP-Lung05 达到主要终点。2）公司与Crescent Biopharma达成合作，将ITGB6 ADCSKB105 海外权益以8,000 万美元首付款和高达12.5 亿美元的里程碑授予Crescent，并以2...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211184208a6995d1f&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211184208a6995d1f&s=b","article_id":"2590512615","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211184208a6995d1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590512615","pubTimestamp":1765382400,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"近日，公司宣布：1）TROP2 ADC芦康沙妥珠单抗联合帕博利珠单抗1L治疗PD-L1 阳性非小细胞肺癌的国内III期临床OptiTROP-Lung05 达到主要终点。2）公司与Crescent Biopharma达成合作，将ITGB6 ADCSKB105 海外权益以8,000 万美元首付款和高达12.5 亿美元的里程碑授予Crescent，并以2,000 万美元首付款和高达3,000 万美元里程碑引进Crescent PD-1 x VEGF双抗CR-001 的中国权益。根据公司公告，公司预计此次合作的两款药物将于1Q26 开展I/II期单药临床，同时双方有权开发引进管线的联用方案。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","06990":"科伦博泰生物-B"},"translate_title":"Kelun Botai Bio-B: SKB2641L lung cancer phase III successfully reached authorization for SKB105","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":1.5},"content_text":"近日，公司宣布：1）TROP2 ADC芦康沙妥珠单抗（SKB264）联合帕博利珠单抗（Keytruda）1L治疗PD-L1 阳性非小细胞肺癌（NSCLC）的国内III期临床OptiTROP-Lung05 达到主要终点。2）公司与Crescent Biopharma达成合作，将ITGB6 ADCSKB105 海外权益以8,000 万美元首付款和高达12.5 亿美元的里程碑授予Crescent，并以2,000 万美元首付款和高达3,000 万美元里程碑引进Crescent PD-1 x VEGF双抗CR-001 的中国权益。评论SKB264 联合K药成为首个在1L NSCLC中达到III期临床主要终点的“ADC+IO”组合。根据公司公告，OptiTROP-Lung05 中，SKB264+K药对比K药治疗1L PD-L1 阳性NSCLC患者在预设的期中分析中，PFS具有显著的统计学意义和临床意义的改善，并且在OS方面观察到获益趋势，公司计划基于该结果在国内提交新增适应症上市申请。1L NSCLC是SKB264 重磅适应症，我们建议重点关注2026 年潜在注册进展和详细数据读出。和Crescent达成双向授权，又一新兴靶点ADC进入视野，同时引入双抗丰富管线。根据公司公告，公司预计此次合作的两款药物将于1Q26 开展I/II期单药临床，同时双方有权开发引进管线的联用方案。我们认为SKB105 作为临床前阶段的新兴靶点ADC资产，本次达成对外授权，给公司带来较好的现金流入的同时也助力其临床开发路径进入快车道。同时，公司引入PD-1 x VEGF双抗，有助于和其自身领先的ADC资产形成协同，探索下一代IO+ADC的联用潜力。盈利预测与估值考虑到授权首付款收入，我们上调2025 年归母净利润预测由亏损6.72 亿元至亏损4.20 亿元，基本保持2026 年归母净利润预测亏损1.73 亿元不变。我们维持跑赢行业评级，基于DCF模型，维持目标价550 港币，较当前股价有33.4%的上行空间。风险研发失败，竞争格局恶化，商业化不及预期，海外业务合作不及预期。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590512615","isCrawlerRequest":true}